Sugi Predict

Sugi Predict / Compounds / SCHEMBL1642073

SCHEMBL1642073

SCHEMBL1642073

CC(C)(C)OC(=O)N[C@@H](CCOS(C)(=O)=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 5/20 0.47
▸ CTSS P25774 4/20 0.47
▸ ALDH1A1 P00352 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ PKM P14618 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ XBP1 P17861 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MAPT P10636 3/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1643165 1.00 CTSK (0.47) CTSKCTSSALDH1A1LMNAPKM
SCHEMBL19954205 1.00 CTSK (0.47) CTSKCTSSALDH1A1LMNAPKM
SCHEMBL4714038 0.93 CTSK (0.46) CTSKCTSSALDH1A1LMNAPKM
SCHEMBL21715590 0.93 CTSK (0.46) CTSKCTSSALDH1A1LMNAPKM
SCHEMBL17846215 0.93 CTSK (0.46) CTSKCTSSALDH1A1LMNAPKM
SCHEMBL17846169 0.92 CTSK (0.45) CTSKCTSSALDH1A1LMNAPKM
SCHEMBL391356 0.88 P2RY2 (0.42) ALDH1A1PKMHPGDMAPT
SCHEMBL22690610 0.88 CTSS (0.42) CTSKCTSSALDH1A1LMNAPKM
SCHEMBL22690612 0.88 CTSS (0.42) CTSKCTSSALDH1A1LMNAPKM
SCHEMBL389645 0.88 P2RY2 (0.42) ALDH1A1PKMHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180346428-A1 PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES NEUROCRINE BIOSCIENCES, INC. 2018-12-06 — — US claimed
US-8765948-B2 Processes for the preparation of uracil derivatives NEUROCRINE BIOSCIENCES, INC. (US) 2014-07-01 — — US claimed
US-20110098472-A1 PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES NEUROCRINE BIOSCIENCES, INC. 2011-04-28 — — US claimed
WO-2009062087-A1 PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES NEUROCRINE BIOSCIENCES, INC. (US) 2009-05-14 — — WO claimed
US-20230072265-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2023-03-09 — — US disclosed
US-11459305-B2 Processes for the preparation of uracil derivatives NEUROCRINE BIOSCIENCES, INC. (US) 2022-10-04 — — US disclosed
EP-2683704-B1 BRANCHED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF SANOFI SA (FR) 2014-12-17 — — EP disclosed
EP-2683704-B1 BRANCHED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF SANOFI SA (FR) 2014-12-17 — — EP disclosed
US-8828995-B2 Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof SANOFI (FR) 2014-09-09 — — US disclosed
US-8828995-B2 Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof SANOFI (FR) 2014-09-09 — — US disclosed
EP-2683704-A1 BRANCHED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF SANOFI (FR) 2014-01-15 — — EP disclosed
WO-2012120053-A1 BRANCHED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF SANOFI (FR) 2012-09-13 — — WO disclosed
WO-2012120053-A1 BRANCHED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF SANOFI (FR) 2012-09-13 — — WO disclosed
US-20110098472-A1 PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES NEUROCRINE BIOSCIENCES, INC. 2011-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180346428-A1 PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES GNRHR, FSHR, GHRHR CTSK 2117/4885CTSS 1872/4885ALDH1A1 2911/4885
US-20110098472-A1 PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES GNRHR, FSHR, GHRHR CTSK 2117/4885CTSS 1872/4885ALDH1A1 2911/4885
US-20230072265-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS BPNT1, GABRA6, GABRA1 CTSK 4837/4885CTSS 4853/4885ALDH1A1 31/4885
US-11459305-B2 Processes for the preparation of uracil derivatives GNRHR, FSHR, GHRHR CTSK 2117/4885CTSS 1872/4885ALDH1A1 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.